Entera Bio (ENTX) Cash from Operations (2021 - 2026)
Entera Bio's (ENTX) quarterly Cash from Operations came in at 3090000.0 in Q1 2026, down 120.09% YoY from 15384255.32 in Q1 2025, and down 68.58% on a QoQ basis from 1833000.0 in Q4 2025.
Entera Bio (ENTX) Cash from Operations (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has 6 years of Cash from Operations data on file, last reported at 3090000.0 in Q1 2026.
- Quarterly Cash from Operations fell 120.09% year-over-year to 3090000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9056000.0 (down 42.39% YoY) and the FY2025 annual result came in at 7370000.0, down 8.1% from the prior year.
- Cash from Operations declined to 3090000.0 in Q1 2026, from 1833000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1335000.0 in Q2 2024 to a low of 4792000.0 in Q1 2022.
- A 5-year average of 2181588.24 and a median of 1862000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 66.42% — and 2026, when it slumped 120.09%.
- Tracing ENTX's Cash from Operations over 5 years: stood at 2011000.0 in 2022, then sank by 30.13% to 2617000.0 in 2023, then soared by 43.94% to 1467000.0 in 2024, then fell by 24.95% to 1833000.0 in 2025, then slumped by 68.58% to 3090000.0 in 2026.
- The last three Cash from Operations figures came in at 3090000.0 (Q1 2026), 1833000.0 (Q4 2025), and 2502000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -3.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.46 Mn |
| Jun 30, 2026 | -3.46 Mn |
| Mar 31, 2026 | -3.09 Mn |
| Mar 31, 2026 | -3.09 Mn |
| Dec 31, 2025 | -1.83 Mn |
| Dec 31, 2025 | -1.83 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Sep 30, 2025 | -2.50 Mn |
| Jun 30, 2025 | -1.63 Mn |
| Jun 30, 2025 | -1.63 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Mar 31, 2025 | -1.40 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Dec 31, 2024 | -1.47 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Jun 30, 2024 | -1.34 Mn |
| Mar 31, 2024 | -1.86 Mn |
| Mar 31, 2024 | -1.86 Mn |